The Effect of Grape Consumption on Increasing the Good Bacteria in the Human Intestine
Effect of Grape Consumption on the Microbiome in Healthy Subjects: A Pilot Study
1 other identifier
interventional
20
1 country
1
Brief Summary
This pilot study will assess the ability of daily consumption of one dose (2 servings) of freeze-dried whole table grape powder, made from conventionally grown grapes to alter the composition of the bacteria that live in the intestines in healthy subjects. The grape powder contains 46g of individually quick frozen (IQF) grapes, which is equivalent to 252g fresh fruit. 20 subjects will will consume the beige diet for 4 weeks followed by one dose (two servings) of standardized Freeze-Dried Whole Table Grape Powder (46g) daily for 4 weeks. The primary objective of this pilot study is to determine changes in the gut microbiome. Stool samples will be collected at 4 and 8 weeks for bacterial DNA to determine changes in the bacteria that live in the intestines. You will be asked to avoid foods rich in polyphenols including dark chocolate and cocoa products, dried herbs, berries, coffee, tea, flaxseeds, nuts (chestnut, hazelnut), olive and artichoke for the duration of the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable healthy
Started Oct 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 5, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 6, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2021
CompletedFirst Submitted
Initial submission to the registry
August 24, 2021
CompletedFirst Posted
Study publicly available on registry
August 27, 2021
CompletedMay 6, 2023
May 1, 2023
5 months
August 24, 2021
May 4, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Change in intestinal microbiome composition
Stool samples will be collected at week 4 and 8 of the intervention periods
Baseline (week 0) to Week 8
Secondary Outcomes (4)
change in fecal cholesterol, cholesterol metabolites, and bile acids
Baseline (week 0) to Week 8
change in blood total cholesterol, LDL and HDL-cholesterol,
Baseline (week 0) to Week 8
digestive Health and General Wellness questionnaires (Rand SF-36)
Baseline (week 0) to Week 8
urine content of syringic acid, and ellagic acid metabolites - ellagic acid, and dimethylellagic acid glucuronide
Baseline (week 0) to Week 8
Study Arms (2)
Table Grape
ACTIVE COMPARATORSubjects will consume 4 weeks of (two servings) of standardized Freeze-Dried Whole Table Grape Powder
Beige Diet
PLACEBO COMPARATORSubjects will consume 4 weeks of a beige diet (low in fiber and low in polyphenols)
Interventions
Eligibility Criteria
You may qualify if:
- Healthy human adults age 18-55 years old (females have to be premenopausal)
- Typically consume low fiber/polyphenol diet (beige diet)
You may not qualify if:
- Eating a high fiber/polyphenol diet or taking any medication or dietary supplement, which interfere with the absorption of polyphenols.
- History of gastrointestinal surgery, diabetes mellitus on medications, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP \>160mmHg, diastolic BP \> 95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.
- Screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.
- Is unable or unwilling to comply with the study protocol.
- Using prebiotics, probiotics, yogurt, and/or any fiber supplements regularly
- Allergy or sensitivity to grapes. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. To determine this, a positive affirmation by the subject of grape ingestion without incident will be requested.
- Taking antibiotics or laxatives within the past 3 months
- Allergy or sensitivity to grapes. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. To determine this, a positive history of grape ingestion without incident will be requested. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded
- Subjects with known allergy to food coloring dyes.
- In the opinion of the study investigator, any subject who demonstrate a risk of non-compliance with study procedure, or one who cannot read, understand or complete study - related materials.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UCLA Center for Human Nutrition
Los Angeles, California, 90024, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Zhaoping Li, MD, PhD
UCLA Center for Human Nutrition
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief, Division of Clinical Nutrition
Study Record Dates
First Submitted
August 24, 2021
First Posted
August 27, 2021
Study Start
October 5, 2020
Primary Completion
March 6, 2021
Study Completion
July 30, 2021
Last Updated
May 6, 2023
Record last verified: 2023-05
Data Sharing
- IPD Sharing
- Will not share